Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib (HM43239) for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Careers
Contact
Events
News
News
Press Releases
Presentations
Events
Q2 2019 Aptose Biosciences Inc. Earnings Conference Call
Aug 6, 2019 • 5:00 pm EDT
Audio
Webcast